UBE3A and Angelman syndrome: As reviewed by Matsui and Corey (2017), in Angelman syndrome model mouse, the administration of antisense oligonucleotides (ASOs), which target the Ube3a‐ATS lncRNA for degradation, partially reversed some cognitive defects associated with the disease in the animals (Meng et al., 2014).